Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
BMRN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$52.93 - $94.85
Previous CloseN/A
Volume465.01K
Average Volume (3M)1.89M
Market Cap
$12.14B
Enterprise Value$12.43B
Total Cash (Recent Filing)$108.96M
Total Debt (Recent Filing)$497.08M
Price to Earnings (P/E)28.8
Beta0.45
Next Earnings
May 01, 2025EPS Estimate
0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.20
Shares Outstanding191,754,170
10 Day Avg. Volume1,807,286
30 Day Avg. Volume1,888,749
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)N/A
Price to Sales (P/S)4.76
Price to Cash Flow (P/CF)18.30
P/FCF Ratio20.50
Enterprise Value/Market Cap1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.47
Enterprise Value/Ebitda19.11
Forecast
1Y Price Target
$97.58Price Target Upside54.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe Phase III PEGASUS trial of Palynziq in adolescents with phenylketonuria met its primary endpoint, demonstrating a significant lowering in blood Phe levels compared to diet alone.
Financial PerformanceBMRN beat expectations by reporting total sales of $747M in 4Q24 which is higher than projections of $712/$708M that represents a +16% YoY growth.
Market ExpansionThe company plans to present detailed results from the study and submit a supplemental NDA for a label expansion to include adolescents, which could broaden the drug's market.
Bears Say
Competitive ThreatEmerging therapies with competitive risk/benefit profiles, such as PTC’s sepiapterin, could pose a competitive threat to Palynziq in the market.
Investor SentimentThe company is executing toward its long-term goals while working to convince skeptical investors of its opportunities and under-appreciated strengths.
Safety ConcernsThere is uncertainty about safety results due to the existing black-box warning for Palynziq, which could affect investor perception.
---
Ownership Overview
1.00% Insiders
36.97% Mutual Funds
0.54% Other Institutional Investors
38.93% Public Companies and
Individual Investors
BMRN FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $52.93 and its highest was $94.85 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
BioMarin Pharmaceutical’s market cap is $12.14B.
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is May 01, 2025 which is in 2 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Feb 19, 2025. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.534 by $0.106.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is 0.68.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 191,754,170 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of $0.64 in its last earnings report, beating expectations of $0.534. Following the earnings report the stock price went up 4.755%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Currently, no hedge funds are holding shares in BMRN
---
BioMarin Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$97.58 (54.15% Upside)
$97.58 (54.15% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $501.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.96%
12-Months-Change
Fundamentals
Return on Equity
8.05%
Trailing 12-Months
Asset Growth
2.15%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
---
BMRN Company Deck
---
BMRN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for BioMarin highlighted strong financial growth and strategic advancements, particularly in VOXZOGO's expansion and enzyme therapy sales. Despite some expected reductions in growth rates for certain enzyme products and increased SG&A expenses, the overall sentiment remains positive due to strong revenue growth, expanded profitability, and promising future outlook.Read More>---
BMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
---
BMRN Stock 12 Month Forecast
Average Price Target
$97.58
▲(54.15% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Regeneron
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
---